Idana | Updates

By Lucas Spohn

Idana surpasses EUR 350,000! - New developments in e-health


Dear Companists,

The adventure of founding a startup requires a healthy dose of certainty and confidence – and a special dose of optimism does not hurt when deciding to pursue an equity crowdfunding campaign. The fact that we have received so much confirmation through Companisto from all those who have provided feedback and contacted us, and especially from the more than 500 Companists who have invested in us since mid-January – what a truly fantastic feeling!


We have reached the €350,000 mark – what’s next?

Since campaign-launch early this year, more than 500 Companists have invested more than €350,000 in Idana, enabling faster growth. The funds from the equity crowdfunding campaign will be used to hire more employees in sales, marketing, administration, and customer support to promote market development. Next to daily business operations, the Companists’ investment also gives us the opportunity to attract additional public funding – which, in turn, allows us to tackle software development more effectively.

Our next goal is to reach the financing limit of €500,000. The additional funds will be used primarily to benefit development and sales and will allow us to further increase our marketing and sales targets by the end of 2018 – thus creating the best conditions for Series A financing in early 2019.


Idana captures the zeitgeist: Developments in the field of e-health.

The latest developments in healthcare and e-health confirm our vision to transform medical processes with digital solutions and show that products like Idana are urgently needed by many healthcare providers.

Doctors are currently discussing the continuation of the ban on remote treatment. So far, it only allows telemedical treatment, such as consultation hours via video calls, if a personal discussion between doctor and patient has already occurred. In February, the Baden-Wuerttemberg Landesärztekammer (Medical Association) approved two model projects in which doctors are now also allowed to provide telemedical advice to patients they do not know, including the DocDirect project supported by the Kassenärztliche Vereinigung (Association of Health Insurance Providers). In May, the Bundesärztetag (Federal Medical Association) will vote on the continuation of the ban on remote treatment. It is quite possible that the controversial law will be overturned and the eHealth market will experience an additional upswing with the possibility of telemedical advice.

These developments provide additional impetus for innovative business models such as Idana, which utilize technological possibilities to redesign existing communication models.


 Recording of the video conference from 19 April 2018


e-health pioneers

We would like to thank you, dear Companists, for your trust and your willingness to join the Idana team as e-health pioneers in the adventure of digitally supported and accompanied medicine!


Idana Team


Best greetings from Freiburg,
Lucas Spohn


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 500,000




22.58 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used. The expected yield is not guaranteed and may turn out to be lower.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 7 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of Idana.
Already registered?    Log in